Several respiratory and autoimmune diseases may be caused, at least in part, by a lack of sufficient native SCGB1A1 protein in patients. We are developing a pharmaceutical therapy to replace SCGB1A1 with the synthetic version (rhSCGB1A1) in respiratory diseases characterized by inflammation and pre-existing SCGB1A1 deficiency.
Secretoglobins are naturally occurring proteins produced in the body by Club Cells. They are some of the most abundant proteins secreted in the airways. Naturally occurring SCGB1A1 is the most abundant protein in the fluid that lines the respiratory tract in both the upper and lower lung, including the sinus cavities. rhSCGB1A1 has the potential to modify, or to help resolve inflamed airways in a wide range of respiratory conditions such as asthma, chronic sinusitis, COPD and pulmonary fibrosis, unlike many treatments that provide symptomatic treatment only. We are developing a platform of pharmaceutical therapies to replace native SCGB1A1 with rhSCGB1A1 in an effort to improve respiratory conditions characterized by inflammation and SCGB1A1 deficiency.
Trove Therapeutics, Inc. is a Delaware biotechnology corporation headquartered in Rockville, Maryland.